Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients.

British journal of clinical pharmacology - 1 Apr 2008

Hirt Déborah, Mentré France, Tran Agnès, Rey Elisabeth, Auleley Solange, Salmon Dominique, Duval Xavier, Tréluyer Jean-Marc

Abstract excerpt

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: * Nelfinavir is an HIV protease inhibitor, substrate of the transporter P-glycoprotein and metabolized via CYP2C19, CYP3A4 and CYP3A5 enzymes. * Pharmacokinetic studies have shown wide interindividual variability of nelfinavir concentrations, some of this variability perhaps caused by variant drug metabolism or transporter genes. * For CYP3A4*1B and CYP3A5*3 polymorphism,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Biotransformation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Body Weight

Share to Cytochrome P-450 CYP2C19

Share to Cytochrome P-450 CYP3A

Share to HIV Protease Inhibitors

Share to Mixed Function Oxygenases

Share to Nelfinavir

Source

Open in PubMed Open full text

Identifiers

PMID: 17922881
DOI: 10.1111/j.1365-2125.2007.03039.x
PMCID: PMC2291390

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients.PMID 17922881Read ↗

Pharmacogenetics of Long‐Term Responses to Antiretroviral Regimens Containing Efavirenz and/or Nelfinavir: An Adult AIDS Clinical Trials Group StudySemantic proximity Read ↗

CYP2C19 genetic variants affect nelfinavir pharmacokinetics and virologic response in HIV-1-infected children receiving highly active antiretroviral therapy.Semantic proximity Read ↗

Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals.Semantic proximity Read ↗

Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.Semantic proximity Read ↗

Pregnancy-Related Effects on Nelfinavir-M8 Pharmacokinetics: a Population Study with 133 WomenSemantic proximity Read ↗

Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.Semantic proximity Read ↗

Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals.Semantic proximity Read ↗

Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism.Semantic proximity Read ↗

Population Approach to Efavirenz Therapy.Semantic proximity Read ↗

No Clinical Impact of CYP3A5 Gene Polymorphisms on the Pharmacokinetics and/or Efficacy of Maraviroc in Healthy Volunteers and HIV-1-Infected Subjects.Semantic proximity Read ↗

Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients.Semantic proximity Read ↗

Efavirenz pharmacogenetics in a cohort of Italian patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.